logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10208019 B1

PDFFull Text
Date of Patent:
Feb. 19, 2019

Filed:

Dec. 13, 2017

Glp-1 receptor agonists and uses thereof

Applicant:

Pfizer Inc., New York, NY (US);

Inventors:

Gary Erik Aspnes, Rockville, RI (US);

Scott W. Bagley, Mystic, CT (US);

John M. Curto, Mystic, CT (US);

Matthew S. Dowling, Old Lyme, CT (US);

David Edmonds, Arlington, MA (US);

Mark E. Flanagan, Gales Ferry, CT (US);

Kentaro Futatsugi, Quincy, MA (US);

David A. Griffith, Sudbury, MA (US);

Kim Huard, Medford, MA (US);

Gajendra Ingle, Groton, CT (US);

Wenhua Jiao, Salem, CT (US);

Chris Limberakis, Pawcatuck, CT (US);

Alan M. Mathiowetz, Quaker Hill, CT (US);

David W. Piotrowski, Waterford, CT (US);

Roger B. Ruggeri, Waterford, CT (US);

Assignee:

Pfizer Inc., New York, NY (US);

Attorney:

Mary J. Hosley

Primary Examiner:

Samantha L Shterengarts

Int. Cl.
CPC ...
C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 401/14 (2006.01); A61K 31/496 (2006.01); A61K 31/4545 (2006.01); A61P 15/10 (2006.01); A61P 17/06 (2006.01); A61P 9/10 (2006.01); A61P 19/06 (2006.01); A61P 25/28 (2006.01); A61P 25/30 (2006.01); A61P 43/00 (2006.01); A61P 1/16 (2006.01); A61P 25/02 (2006.01); A61P 3/04 (2006.01); A61P 19/02 (2006.01); A61P 3/10 (2006.01); A61P 13/12 (2006.01); A61P 25/18 (2006.01); A61P 1/00 (2006.01); A61P 15/00 (2006.01); A61P 25/16 (2006.01); A61P 3/00 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61P 1/00 (2018.01); A61P 1/16 (2018.01); A61P 3/00 (2018.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); A61P 9/10 (2018.01); A61P 13/12 (2018.01); A61P 15/00 (2018.01); A61P 15/10 (2018.01); A61P 17/06 (2018.01); A61P 19/02 (2018.01); A61P 19/06 (2018.01); A61P 25/02 (2018.01); A61P 25/16 (2018.01); A61P 25/18 (2018.01); A61P 25/28 (2018.01); A61P 25/30 (2018.01); A61P 43/00 (2018.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01);
Abstract

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

Find Patent Forward Citations

Loading…